Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Beats Q2 2025 Revenue Estimates and Posts Narrower Loss Than Expected Arcutis Biotherapeutics (ARQT) beats Q2 2025 revenue and EPS estimates with $81.5M in sales, driven by strong ZORYVE demand. Shares rise post-earnings.
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with eczema.
Rebound Or Fakeout? The 200-Day MA Holds The Key To The Next Big Move A discussion whether the rebound could sustain, the worst scenario and the potential target price for the S&P 500.
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio? Top performers last week: DGNX (108.29%), NEXT (25.07%), CELH (21.60%), SIG (21.08%), NFE (20.63%), MRP (16.61%), ARQT (16.35%), LCID (15.79%), CPRX (15.27%), STNE (14.20%). Are they in your portfolio?
What's Going On With Arcutis Biotherapeutics Stock Monday? Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate atopic dermatitis.
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
